This point is fundamental since it has been demonstrated that balancing glucose metabolic pathways generates a more potent response to PD-L1 silencing than exclusively inhibiting glycolysis by shaping less immune-suppressive tumor micro-environments. Here, CD274 is linked to neoplasm.